Completed PHASE1 INTERVENTIONAL 1-arm NCT02571192

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects

Sponsor: Mirum Pharmaceuticals, Inc.

Conditions Non-Alcoholic Steatohepatitis

Interventions 5.95 μCi RAD SHP626

Updated 7 times since 2017 Last updated: Apr 30, 2019 Started: Oct 1, 2015 Primary completion: Oct 1, 2015 Completion: Oct 1, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non-Alcoholic Steatohepatitis and is currently completed. Mirum Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jun 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mirum Pharmaceuticals, Inc.

Data source: Mirum Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States